RxDoctor Payments Data

Skye Nehs, PA

Medical · Gresham, ORNPI 1740515097

Payments from drug & device makers

$912in general payments, 2019–2025

Across 28 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$246
  • AstraZeneca$129
  • Novartis$110
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$108
  • E.r. Squibb & Sons, L.L.C.$86
  • Heartflow, Inc.$51
  • plus $181 from 6 others

What the payments were for

  • Food & beverage$79888%
  • Education$11412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 70th percentile of 364 medical providers in Oregon.

See all medical providers in Oregon

Medicare billing

Part B allowed, 2024
$37,991
Medicare patients
244
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban620$775,693
JardianceEmpagliflozin200$243,793
EntrestoSacubitril/Valsartan126$183,854
XareltoRivaroxaban122$141,834
Repatha SureclickEvolocumab83$72,612
FarxigaDapagliflozin Propanediol39$50,930
Praluent PenAlirocumab22$21,390
BrilintaTicagrelor22$20,760
Metoprolol Succinate999$13,397
MultaqDronedarone Hcl11$11,236
Potassium Chloride381$10,087
Atorvastatin Calcium698$8,911
Torsemide226$5,783
Losartan Potassium344$4,096
Furosemide575$3,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$775,693620 claims
NovartisEntresto$110$183,854126 claims
AstraZenecaFarxiga, Brilinta$129$71,69061 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 364 medical providers in Oregon.

Other medical in Gresham

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →